Adipo Therapeutics

Purdue University

Adipo Therapeutics is supporting millions of obese people living with diabetes. While current treatment approaches focus on increasing exercise, decreasing food intake, and increasing insulin, Adipo believes there is another option. Our promise to the millions of obese people living with diabetes is to transform the management of their disease by changing energy-storing white fat into energy-burning brown fat. Transformation of adipose tissue through browning has the potential to use the body’s own physiology to raise energy expenditure, reduce adiposity, and improve insulin resistance.


Karen Wurster, CEO (DeepTechU Presenter)

Karen Wurster is an experienced pharmaceutical leader with over 25 years of experience in development, launch and commercialization of blockbuster products in the diabetes market. Karen has a bachelor’s of science degree in Biochemistry and an MBA from Indiana University’s Kelley School of Business.

Meng Deng, PhD, Founder and President

Meng Deng, PhD, is the Founder and President of Adipo Therapeutics. In addition, he serves as the Director for the Regenerative Matter Laboratory and an Assistant Professor of Agricultural and Biological Engineering, Biomedical Engineering, and Materials Engineering at Purdue University. The breakthrough technology of Adipo Therapeutics stems from his strong commitment and 15+ years of experiences on development of biomaterials-based translational technologies for cell engineering, tissue engineering, and drug delivery. Dr. Deng is a faculty fellow of Entrepreneurial Leadership Academy at Purdue University and continues to work within the Purdue entrepreneurial ecosystem and Purdue Foundry in the development and commercialization of Adipo Therapeutics proposed technology platform. Dr. Deng received a B.E. in Chemical Engineering in 2004 from Tsinghua University, China and a PhD in Chemical Engineering from the University of Virginia in 2010. Dr. Deng has more than 50 publications, one edited book, and 11 patents/disclosures in the fields of biomaterials, drug delivery, nanotechnology, and regenerative engineering.

Matt Sheetz, MD, PhD, Senior Medical Advisor

Matt Sheetz, MD, PhD brings extensive background in diabetes and metabolism drug development, with a focus on blood glucose control and diabetic complications, for which he has multiple publications. He offers over 25 years of pharmaceutical experience at Eli Lilly, Hoechst Marion Roussel, and Marion Merrell Dow where he advanced new diabetes treatments from pre-clinical through successful FDA IND and NDA submissions. Dr. Sheets experiences include: submission, regulatory response, and appeal to US FDA (including presentation and defense of position to audience including Office and Division Directors); Submission to EMA; Regulatory Affairs Certification (RAC) in 2007; multiple clinical study reports, briefing documents, protocol development for Phase I-IV clinical research; and leader of discovery biology laboratory. Dr. Sheets educational background includes and MD from the University of Chicago, and PhD in Biochemistry from the University of Chicago, and a BA in Chemistry from Albion College.

Roger Miller, Vice President, Operations

Roger Miller, MSM/MBA serves as the Vice President of Operations for Adipo. He brings more than 50 years of experience in the pharmaceutical industry and biotech start-ups including leadership roles in R&D, Manufacturing, Quality and HR, and Corporate Business Development. His experience has been built in roles at Eli Lilly, AcquiRight, Targanta, BioCritica, Iterion Therapeutics, Salarius Pharmaceuticals, and Apexian Pharma (Apex Therapeutics). Roger�s educational background includes Purdue University, Krannert Graduate School of Management, Master of Management (MSM/MBA) in Operations, Purdue University (IUPUI), Master of Science in Physical Chemistry, Indiana University (IUPUI), Bachelor of Arts in Chemistry.